Lymphatica is a clinical stage medical device development company that has designed and patented the first implantable system for chronic lymphedema treatment, which will improve the quality of life of millions of patients in the world.
Chronic lymphedema is a common side effect of cancer therapies that causes chronic swelling of the limbs, pain and recurrent infections, leading to a state of chronic disability. More than 10 million people in Europe and US have lymphedema.
Lymphatica is a new hope for the patient and a new tool for healthcare specialists.

News

30.03.2023 15 startups contest to win CHF 100,000 (startupticker.ch)
09.06.2021 First Venture Leaders Medtech selected (startupticker.ch)
03.12.2020 Seven digit investment for Lymphatica (startupticker.ch)

Milestones/News